anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
=== Other === Global antipsychotic utilization has seen a steady growth since the introduction of atypical (second-generation) antipsychotics and this is ascribed to off-label use for many other unapproved disorders. Besides the above uses antipsychotics may be used for obsessive–compulsive disorder, post-traumatic stress disorder, personality disorders, Tourette syndrome, autism and agitation in those with dementia. Evidence however does not support the use of atypical antipsychotics in eating disorders or personality disorder. The atypical antipsychotic risperidone may be useful for obsessive–compulsive disorder. The use of low doses of antipsychotics for insomnia, while common, is not recommended as there is little evidence of benefit as well as concern regarding adverse effects. Some of the more serious adverse effects may also occur at the low doses used, such as dyslipidemia and neutropenia, and a recent network meta-analysis of 154 double-blind, randomized controlled trials of drug therapies vs. placebo for insomnia in adults found that quetiapine did not demonstrated any short-term benefits in sleep quality. Low dose antipsychotics may also be used in treatment of impulse-behavioural and cognitive-perceptual symptoms of borderline personality disorder. Despite the lack of evidence supporting the benefit of antipsychotics in people with personality disorders, 1 in 4 who do not have a serious mental illness are prescribed them in UK primary care. Many people receive these medication for over a year, contrary to NICE guidelines.
=== Children === Babies are at increased risk of developing iron deficiency anemia due to their rapid growth. Their need for iron is greater than they are getting in their diet. Babies are born with iron stores; however, these iron stores typically run out by 4–6 months of age. In addition, infants who are given cow's milk too early can develop anemia due to gastrointestinal blood loss. Children who are at risk for iron-deficiency anemia include:
Korolev received word about von Braun's 1956 Jupiter-C test and, mistakenly thinking it was a satellite mission that failed, expedited plans to get his own satellite in orbit. Since the R-7 was substantially more powerful than any of the US launch vehicles, he made sure to take full advantage of this capability by designing Object D as his primary satellite. It was given the designation 'D', to distinguish it from other R-7 payload designations 'A', 'B', 'V', and 'G' which were nuclear weapon payloads. Object D dwarfed the proposed US satellites, having a weight of 1,400 kilograms (3,100 lb), of which 300 kilograms (660 lb) would be composed of scientific instruments that would photograph the Earth, take readings on radiation levels, and check on the planet's magnetic field. However, things were not going along well with the design and manufacturing of the satellite, so in February 1957, Korolev sought and received permission from the Council of Ministers to build a Prosteishy Sputnik (PS-1), or simple satellite. The council also decreed that Object D be postponed until April 1958. The new Sputnik was a metallic sphere that would be a much lighter craft, weighing 83.8 kilograms (185 lb) and having a 58-centimeter (23 in) diameter. The satellite would not contain the complex instrumentation that Object D had, but had two radio transmitters operating on different short wave radio frequencies, the ability to detect if a meteoroid were to penetrate its pressure hull, and the ability to detect the density of the Earth's thermosphere.
Sources: en.wikipedia.org
PEAKS and NovoHMM had the best sensitivity in both QSTAR and LCQ data as well. However, no evaluated algorithms exceeded a 50% of exact identification for both data sets. Recent progress in mass spectrometers made it possible to generate mass spectra of ultra-high resolution [1]. The improved accuracy, together with the increased amount of mass spectrometry data that are being generated, draws the interests of applying deep learning techniques to de novo peptide sequencing. In 2017 Tran et al. proposed DeepNovo, the first deep learning based de novo sequencing software. The benchmark analysis in the original publication demonstrated that DeepNovo outperformed previous methods, including PEAKS, Novor and PepNovo, by a significant margin. DeepNovo is implemented in python with the Tensorflow framework. To represent a mass spectrum as a fixed-dimensional input to the neural-network, DeepNovo discretized each spectrum into a length 150,000 vector. This unnecessarily large spectrum representation, and the single-thread CPU usage in the original implementation, prevents DeepNovo from performing peptide sequencing in real time. To further improve efficiency of de novo peptide sequencing models, Qiao et al. proposed PointNovo in 2020. PointNovo is a python software implemented with the PyTorch framework and it gets rid of the space consuming spectrum-vector-representation adopted by DeepNovo. Comparing with DeepNovo, PointNovo managed to achieve better accuracy and efficiency at the same time by directly representing a spectrum as a set of m/z and intensity pairs.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\Lambda -\mu S-{\frac {\beta IS}{N}}\\[8pt]{\frac {dI}{dt}}&={\frac {\beta IS}{N}}-\gamma I-\mu I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R\end{aligned}}}
24 May – Three crew members are injured in an engine room explosion aboard a ship berthed in Bluff. 26 May: Two of the New Zealand Government's "non-financial benefit sanctions" come into force: namely money management payment cards and community work experience activities. Heavy rain leads to flooding in Nelson and Westport. 27 May: Police Commissioner Richard Chambers overturns a directive from March 2025 instructing Police officers not to investigate "lower value" thefts, petrol drive-offs, shoplifting and fraud crimes. The Department of Conservation proposes axing 84 jobs to meet a Government directive for a 6.5 percent reduction in spending. 28 May: Health Minister Simeon Brown and Finance Minister Nicola Willis announce that the Government will invest in 126 additional beds and treatment spaces at Wellington Hospital. Anti-mining protesters picket ANZ Bank branches in Dunedin and other centres to protest against the bank's relationship with coal company Bathurst Resources, which has applied for a fast-track consent to mine the Denniston Plateau. 29 May: The Transport Accident Investigation Commission (TAIC) launches an explosion into a boiler room explosion aboard a ship berthed in Bluff that occurred on 24 May. A car crash causes a power outage and traffic disruption in Rotorua's Pukehangi suburb. 30 May: Police launch a review into how many cases of retail crime were filed after the rescindment of a controversial directive directing the Police not to investigate lower-value retail crimes.
Sources: en.wikipedia.org
with two different fluorophores and the antibiotic levofloxacin, showcasing the potential of covalently functionalized recombinant spider silk proteins as biomaterials with enhanced properties. The researchers were able to successfully conjugate
The MNHN has been called "the Louvre of the Natural Sciences". Its largest and best-known gallery is the Grand Gallery of Evolution, located at the end of the central alley facing the formal garden. It replaced an earlier Neoclassical gallery built next to the same by Buffon, opened in 1785, and demolished in 1935. It was proposed in 1872 and begun in 1877 by the architect Louis-Jules André, a teacher at the influential École des Beaux-Arts in Paris. It is a prominent example of Beaux Arts Architecture. It was opened in 1889 for the Paris Universal Exposition of 1889, which also presented the Eiffel Tower. It was never fully completed in its original design; it never received the neoclassical entrance planned for the side of the building away from the garden, facing Rue Geoffroy-Saint-Hilaire. The facade of the building was designed specifically as a backdrop for the garden. The facade facing the garden is divided into eleven traverses. Ten are decorated with sculpted medallions honouring prominent French scientists associated with the MNHN. The central traverse has a larger marble statue of a woman seated holding a book, in a pose similar to that of statue of Buffon facing the building. The statues are the work of Eugene Guillaume, a pupil of the sculptor Pradier. While the building exterior was neo-classical, the iron framework of the interior was extremely modern for the 19th century, like that of the Gare d'Orsay railroad station of the same period.
=== Internal genetic structure === The internal genetic structure of the Han Chinese is consistent with the vast geographical expanse of China. The reference population for the Han Chinese used in Geno 2.0 Next Generation is 81% Eastern Asia, 2% Finland and Northern Siberia, 8% Central Asia, and 7% Southeast Asia & Oceania. The recorded history of large migratory waves over the past several millennia have also engendered the emergence of diverse Han subgroups, who display slight but discernible physical and physiological differences. Although genetically similar, Han Chinese subgroups exhibit a north–south stratification in their genetics, with centrally placed populations acting as conduits for outlying ones. Despite no clear genetic divide between the north and south due to the Han Chinese being a clinal population, many studies simply categorize the Han Chinese into two subgroups out of convenience: Northern and Southern Han Chinese. Several genetic studies show that both Northern and Southern Han Chinese share ancestry with Neolithic Chinese populations from the Central Plains. Northern Han Chinese and Southern Han Chinese can be modeled as having Neolithic Yellow River and Kra-Dai-speaking ancestries, although Kra-Dai ancestry is more common in Southern Han. Despite shared Neolithic Yellow River ancestry, Han sub-groups slightly differ in their ancestral components, reflective of their vast demographic history. Specifically, they tend to share some maternal ancestry with geographically close minority groups.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.